A Corewell Health study suggests that men who have longer prostatic urethras, the part of the urethra that travels through the prostate, may be at a higher risk of experiencing moderate, often chronic urinary side effects after receiving radiation for prostate cancer.
The Decipher Prostate Genomic Classifier predicts which patients with metastatic cancer are likely to benefit from treatment intensification with the chemotherapy docetaxel and which are not likely to benefit and can therefore avoid unnecessary toxicity, according to findings by University College London and Veracyte, Inc., a genomic diagnostic company.
